Antiviral activity of a pyrazino-pyrazine derivative.
The 2,3-dihydroxy-6-bromo-pyrazino-[2,3-beta]-pyrazine is a substance selected during the antiviral screening of pyrazino-pyrazine derivatives. The compound shows antiviral activity in vitro against measles, NDV, some influenza viruses and against herpes simplex and zoster, infectious canine hepatitis and vaccinia viruses. It had no effect on ECHO 9 virus. Therapeutic trials showed activity also on herpetic keratoconjunctivitis experimentally induced in rabbits.
D006516:Adenoviruses, Canine / Q000187:drug effects; D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology* / Q000627:therapeutic use; D003588:Cytopathogenic Effect, Viral / Q000187:drug effects; D006367:HeLa Cells / Q000187:drug effects; D014645:Herpesvirus 3, Human / Q000187:drug effects; D007635:Keratitis, Dendritic / Q000188:drug therapy; D008459:Measles virus / Q000187:drug effects; D008826:Microbial Sensitivity Tests; D008938:Mitosis / Q000187:drug effects; D009522:Newcastle disease virus / Q000187:drug effects; D011719:Pyrazines / Q000494:pharmacology* / Q000627:therapeutic use; D011817:Rabbits; D018139:Simplexvirus / Q000187:drug effects; D014616:Vaccinia virus / Q000187:drug effects
D000998:Antiviral Agents; D011719:Pyrazines